work through our the We've solid company's the since joining the few I'm collaboration going to pipeline during to and company. commitment next progress Thank the like made in-depth excited candidates. I'd I more compliment spend this for product short-time I'm you August. team in taking minutes their I've and Jim. joined the you, look Oncternal hard since opportunities for a about very witnessed and at
the is trial in a or would program pathway, clinical MCL. to currently we ibrutinib antibody CLL the which Our in lead their RORX cirmtuzumab. with of is patients clinical combination monoclonal call X/X pathway, RORX designed It’s Phase inhibit which also
genesis, a important for disease is because it's implicated diseases. resistance. has an progression care cancer these that in believe target with We patients of RORX become treatment ibrutinib standard
C.R. a benefit. patients responses significant have patients Therefore, an clinical number complete a without ibrutinib ibrutinib or may the uncommon in believe achieving However, complements provide that agent with CRs increase we alone. treated been toxicity that to of meaningful
of randomized was the cirmtuzumab announced of outcomes X/X this our confirming X the the the Phase cohorts opening on with for from Phase favorable In dose based CLL. enrollment finding open study. trial of clinical to with X dose and study August, portion Decision combined the in patients ibrutinib Phase of we
interim patients first who the XX completed The treatment. with CLL for response the received percent had and rate nine of data with combination recommended the objective regimen was who valuable XXX the dosing weeks
reported We continue well-tolerated that to safety is with see ibrutinib which alone. profile, a consistent for
results with enrollment of Last decision the announced of our the this of cohort which opening trial, tolerated safety X/X from dose-finding was of reported combined again well to with based patients Phase a open we included that the cell lymphoma. consistent indicated clinical for cirmtuzumab month, was the interim Phase profile alone. cohort The favorable ibrutinib in expansion that expansion Xb mantle the combination on with ibrutinib with trial in
and prior responses an Complete had to trial. this participating multiple transplant. transplant received two autologous received regimens were previously on One and observed had failed patients who in patient allogeneic an
an CAR-T The other and autologous received had therapy. transplant
already The for a been complete months. response sustained first XX of period has
or in also investigator the in patients is of cirmtuzumab cancer. Now, with negative, trial being HerX breast X with treatment studied advanced combination unresectable locally metastatic the sponsored for paclitaxel Phase clinical
be the expect year. from presented later that the conference will We at study interim data this scientific
I'm gears. switching
TKXXX. is program clinical second Our
oncoproteins the molecule – of the family clinic is biologic transcription first of factor a the investigational, tumor enter in ETS small first to which activity that’s types. investigational The variety a inhibit to designed
his indication refractory limited compound first lead rare treatment for Our Ewing relapse bone options. pediatric the for chemotherapy. cancer a is Sarcoma, At with sign
we've this pleased as FDA Nearly that by fusion for of ETFs already received fast Sarcoma and from designation program. proteins Ewing all TKXXX. targeted track cases express I'm oncogenes orphan drug in status
are as We a single patients evaluating for in with trial X agent, and vincristine Phase in clinical Sarcoma. a Ewing with TKXXX combination
number to as patient recently a with This single we encouraged clinical continue to sustained is of other which explore devastating preclinical malignancies, also novel response potentially very target We're this agent a TKXXX first to in the applicable agent studies. disease. by reported in a
cells have against patient's effort direct therapies program been Medicine to the target CAR-T CAR-T engage This in supported immune use University California T development preclinical to which has system San from a third of a react and in is CIRM. or an research engineered specific collaboration grant on Our California that Diego. on the Institute cells RORX by therapy, been some. for cancer Regenerative with in to bind is the
[XXX] that of to normal variety tissues. very wide a attractive blood CAR-T to and a with uses common our cells that's but cancerous CAR-T not across to expression human believe this most target bind tumors. is designed We to The for of high a solid cirmtuzumab therapy component but cancers of recognize due antibody, affinity, fragment targeting RORX
across our year. As development we're first against pipeline. objective is pleased half with further seeing progress the select CAR-T Jim mentioned, malignancies the in hem solid next to Overall, we’re our of entire for
review with Rich our our that, Chief it results. I'll turn Financial to third financial to quarter Officer, And over Vincent
